Helen Angell is an Associate Principal Scientist in the Oncology, Translational Science team in the IMED Biotech Unit in Cambridge, UK. Helen received her Ph.D. ‘Immune Modulation of the Tumour Microenvironment’ from the University of Nottingham School of Pharmacy, funded by AstraZeneca and EPSRC (Engineering and Physical Sciences Research Council). Upon completing her doctorate, Helen began working in the Laboratory of Integrative Immunology at the Cordeliers Research Centre, Paris. A joint MedImmune-funded postdoc, here Helen was involved in the development and implementation of the ‘Immunoscore’. In addition, Helen undertook research into the characterisation and phenotyping of immune subpopulations, cytokines, chemokines and tumour alteration, associated with colorectal cancer progression, recurrence and metastasis. In January 2014 Helen joined AstraZeneca’s Oncology iMed team as a Senior Scientist within the Molecular Pathology Group, Translational Science. Focusing on development of the leading Immuno-Oncology portfolio, Helen has devised strategies for segmentation of immunotherapy and small molecule combination studies with the aim to enhance patient selection for clinical trials, as well as leading external collaborations to further accelerate scientific progress in this field.

 Engineering and Physical Sciences